Congratulations to Neuroscience Institute Medical Director David Vossler, MD, FAAN, for the recent publication of a research paper for which he was lead author. The research took place over a seven year period with 108 sites participating worldwide.
The study entitled, “Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: Results form a multicenter, open-label trial,” was recently published in Epilepsia, Official Journal of the International League Against Epilepsy.
The study’s results support the use of lacosamide as long-term monotherapy treatment for adults with partial-onset seizures. Why is this significant? Epilepsy will occur in approximately one in 26 people over their lifetime, and partial-onset (focal) seizures (POS) are the predominant seizure type in adults with epilepsy.
Key Points of the Study
- This was a 2-year open-label extension to a multicenter, double-blind, conversion-to-monotherapy study
- The majority of patients still in the study at the 12- and 24-month points, were taking LCM monotherapy
- Lacosamide monotherapy was generally well tolerated for up to 2 years of treatment
- The median LCM dose was 500 mg/day, and doses up to 800 mg/day were tolerated
- Post hoc analyses of responder rates suggest that reductions in seizure frequency were maintained over long-term LCM treatment